Background-Adeno-associated virus type 1/sarcoplasmic reticulum Ca 2ϩ -ATPase was assessed in a randomized, double-blind, placebo-controlled, phase 2 study in patients with advanced heart failure. Methods and Results-Thirty-nine patients received intracoronary adeno-associated virus type 1/sarcoplasmic reticulum Ca 2ϩ -ATPase or placebo. Seven efficacy parameters were assessed in 4 domains: symptoms (New York Heart Association class, Minnesota Living With Heart Failure Questionnaire), functional status (6-minute walk test, peak maximum oxygen consumption), biomarker (N-terminal prohormone brain natriuretic peptide), and left ventricular function/remodeling (left ventricular ejection fraction, left ventricular end-systolic volume), plus clinical outcomes. The primary end point success criteria were prospectively defined as achieving efficacy at 6 months in the group-level (concordant improvement in 7 efficacy parameters and no clinically significant worsening in any parameter), individual-level (total score for predefined clinically meaningful changes in 7 efficacy parameters), or outcome end points (cardiovascular hospitalizations and time to terminal events). Efficacy in 1 analysis had to be associated with at least a positive trend in the other 2 analyses. This combination of requirements resulted in a probability of success by chance alone of 2.7%. The high-dose group versus placebo met the prespecified criteria for success at the group-level, individual-level, and outcome analyses (cardiovascular hospitalizations) at 6 months (confirmed at 12 months) and demonstrated improvement or stabilization in New York Heart Association class, Minnesota Living With Heart Failure Questionnaire, 6-minute walk test, peak maximum oxygen consumption, N-terminal prohormone brain natriuretic peptide levels, and left ventricular end-systolic volume. Significant increases in time to clinical events and decreased frequency of cardiovascular events were observed at 12 months (hazard ratioϭ0.12; Pϭ0.003), and mean duration of cardiovascular hospitalizations over 12 months was substantially decreased (0.4 versus 4.5 days; Pϭ0.05) on high-dose treatment versus placebo. There were no untoward safety findings.
Experimental models of heart failure have demonstrated that increasing the expression of SERCA2a in cardiomyocytes normalizes intracellular calcium cycling, restores lusitropic and inotropic function, corrects cardiac metabolism, and results in significant improvement in cardiac function, energetics, and survival. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In large-animal models of heart failure, doses of 1ϫ10 12 DNase-resistant particles were beneficial and resulted in increased SERCA2a expression in the myocardium. 13 In addition, adeno-associated virus type 1 (AAV1)/SERCA2a increases coronary blood flow by transduction of coronary endothelial cells via upregulation of endothelial nitric oxide synthase. 18, 19 
Clinical Perspective on p 313
A first-in-human, phase 1 trial was conducted to restore the levels of this key enzyme in patients with advanced heart failure by gene transfer with the use of a viral vector (AAV1) to deliver the SERCA2a gene, demonstrating safety and feasibility. 20, 21 Accordingly, a phase 2 trial was performed to further evaluate the effects of 3 doses of AAV1/SERCA2a versus placebo in a similar, advanced heart failure population.
Methods

Study Overview
The phase 2 Calcium Upregulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) trial is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study that compares the use of AAV1/SERCA2a administered by intracoronary infusion at 3 dose levels with placebo over a 12-month period plus a 2-year telephonic follow-up. All patients continued to receive optimal medical and device therapy for their heart failure. Detailed information about the phase 1 and 2 study designs and results of the phase 1 trial have been published previously. 20, 21 The primary end point in phase 2 was prospectively evaluated at 6 months, with additional prespecified analysis through 12 months. The study was approved by institutional review boards and institutional biosafety committees at each site, and written informed consent was obtained from all patients before screening.
Before the CUPID study was conducted, the impact of AAV1/ SERCA2a on clinical outcomes was not known. Therefore, in this small trial, we attempted to use an end point approach in which concordant changes across multiple end points are required to demonstrate efficacy, which results in a very low false-positive rate. The analysis of multiple end points in early heart failure trials (versus a single primary end point such as ejection fraction [EF]) has also been suggested recently by the Food and Drug Administration in a cross-center guidance document pertaining to cellular therapy for cardiac disease. 22 These concepts were discussed at the Ninth Cardiovascular Clinical Trials Workshop. 23 The primary end point success criteria in the CUPID trial consisted of 4 efficacy domains, as well as a fifth domain that examined clinical outcomes. The efficacy domains are described below and in more detail in the online-only Data Supplement. The primary efficacy end point was prospectively defined by evaluating concordant changes in end points for group-and individual-level comparisons and clinical outcomes at 6 months. 20, 21 Given both the between-and withinpatient variability in each of 7 efficacy parameters, it was not realistic to expect statistically significant changes at the Յ0.05 level. However, on the basis of the primary end point prespecified in the analysis plan at the 6-month analysis, the false-positive rate (the probability of concordant changes in all efficacy parameters, individual patient improvements, and improvement in duration of cardiovascular hospitalizations) was only 2.7% (as determined by permutation test).
Study Population
Patients enrolled had New York Heart Association (NYHA) class III/IV heart failure, left ventricular (LV) EF Յ35%, maximal oxygen uptake (V O 2 max) Յ20 mL/kg per minute, and implantable cardiac defibrillators and were on stable (at least 30 days) optimal outpatient therapy for heart failure. Patients were enrolled into the study in 2 phases. In the early phase, patients were randomized to either placebo, low-dose AAV1/SERCA2a (6ϫ10 11 DNase-resistant particles), or mid-dose AAV1/SERCA2a (3ϫ10 12 DNase-resistant particles). Addition of a third dose was prespecified, and high-dose AAV1/SERCA2a (1ϫ10 13 DNase-resistant particles) was introduced after safety data from patients in the phase 1 trial had been reviewed by the Data Monitoring Committee. As planned, the remaining 39 patients were randomized to placebo or the low, mid, or high dose to maintain the overall target randomization ratio of 13:8:8:8. A flow diagram presenting the enrollment, intervention allocation, follow-up, and data analysis with number of patients for each group is provided in Figure 1 . Results stratified by randomization scheme are presented in the online-only Data Supplement.
Only patients with undetectable neutralizing antibodies against AAV1 (titer Ͻ1:2), which can block entry of the vector into the target cells, 20, 21, 24 were eligible. As depicted in Figure 1 , 509 patients were prescreened in a separate feeder protocol (protocol No. CELL-002) with few restrictive inclusion and exclusion criteria and with 2 additional objectives of evaluating the incidence of neutralizing antibodies against AAV1 in a large heart failure population and obtaining sufficient serum samples with a full range of titers for development of an enzyme-linked immunosorbent assay. Of these 509 patients, 63 with negative AAV1 neutralizing antibodies were considered as candidates for the CUPID protocol and were evaluated further.
Product Source and Administration
AAV1/SERCA2a was manufactured by Targeted Genetics Corporation (Seattle, WA) and Celladon Corporation (La Jolla, CA). It was administered by antegrade epicardial coronary artery infusion over a 10-minute period in a cardiac catheterization laboratory (percutaneous intracoronary delivery without any vessel balloon occlusion) with the use of standard 5F or 6F guide or diagnostic catheters, as described previously. 21 Administration of nitroglycerin (either intracoronary bolus before infusion or intravenous before and during infusion or both) was routinely performed. Patients with total occlusion of multiple coronary arteries were excluded from the study.
Statistical Methods
Primary End Point Constituents
These methods are described in detail in the online-only Data Supplement. Briefly, safety, a key component of this phase 2 trial, is evaluated by the incidence and severity of all adverse events.
The efficacy domains are symptomatic, functional, biomarker, and LV function/remodeling. Each domain included end points typically used to assess interventions in heart failure trials. To establish a definition of clinically meaningful changes for each end point, the study sponsor consulted experts in the treatment of heart failure, reviewed published data from clinical studies of approved therapies for parameter variability and changes, and considered the predictive power of changes in a given parameter for clinical outcomes, including mortality/morbidity in patients with advanced heart failure. These prospectively defined clinically meaningful changes for AAV1/SERCA2a versus placebo have been described previously 20, 21 and are discussed in more detail in the online-only Data Supplement. The group-level analysis compared mean changes from baseline to 6 months in the 4 efficacy domains (for a total of 7 end point values) for placebo versus each of 3 dose levels of AAV1/SERCA2a. For the individual-level analysis, each patient's baseline value was compared with their 6-month value on similar end points used for the group-level analysis, and a numeric score was calculated. The end points were scored as ϩ1 for improved, Ϫ1 for worsened, and 0 if the change in that end point did not meet the prespecified threshold for change. The mean numeric score in the placebo group was then compared with those in each of the 3 dose levels of AAV1/ SERCA2a. For the group-level analysis, the clinically meaningful thresholds for change 20, 21 in the 4 domains are defined as follows: (1) symptomatic: NYHA classification, mean change from baseline Ͼ0; Minnesota Living With Heart Failure Questionnaire, change of 10 points on total score; (2) functional: distance walked during the 6-minute walk test, change of 50 m; V O 2 max assessed by cardiopulmonary exercise testing (exercise V O 2 max), change of 1.5 mL/kg per minute; (3) biomarker: N-terminal prohormone brain natriuretic peptide, change of 35% or 300 pg/mL, whichever is greater; (4) LV function/remodeling: echocardiographically derived LVEF, change of 3% (absolute); and LV end-systolic volume, change of 20 mL or 10%, whichever is greater.
For individual-level analysis, all thresholds for clinically meaningful change were as described above except for LVEF and NYHA, which were defined as a change of 5% (absolute) and 1 NYHA class, respectively. 21 In addition to the aforementioned group-and individual-level analyses, there was also an outcome analysis: time to death (or ventricular assist device implantation or heart transplantation), placebo versus each of 3 dose levels of AAV1/SERCA2a, based on Kaplan-Meier analysis; and duration of cardiovascular hospitalizations. Additional prospectively defined analyses include time to multiple, recurrent clinical events, 25 including worsening heart failure, myocardial infarction, heart failure hospitalizations, cardiovascular death, ventricular assist device implantation, or transplantation. Cumulative rate of recurrent clinical events was adjusted for different follow-up times due to terminal events (informative censoring). The nonparametric estimator 26 was used. The respective 12-month hazard ratios for recurrent clinical events were calculated with a joint frailty model. 27 The calculation of cumulative event rates at each time point takes into account the number of patients still at risk of recurrent events. A similar approach was applied to the analysis of the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) study data on recurrent hospitalizations in the presence of death. 28 Over time, some patients may be lost to follow-up, die from noncardiovascular causes, or have a terminal cardiovascular event (LV assist device, transplantation, cardiovascular death). These patients either cannot be followed or are considered treatment failures (in CUPID, patients were taken off-study after LV assist device implantation or heart transplantation), and therefore they are removed from the risk set (a subset of patients for whom recurrent events may still occur in the future). Finally, a secondary end point, defined as days after transplantation or ventricular assist device implantation, hospitalization, or not alive, was compared between treatment groups.
Primary End Point Success Criteria
The primary end point success criteria were defined as achieving efficacy in either (1) the group-level analysis, with improvement in Ն2 of 4 efficacy domains at PϽ0.2; or (2) the individual-level analysis, with improvement at PϽ0.2; or (3) the outcome end point, time to death (or ventricular assist device/transplantation) analysis based on the Kaplan-Meier approach with AAV1/ SERCA2a better than placebo (PϽ0.2). If Kaplan-Meier analysis is in favor of AAV1/SERCA2a but PϾ0.2, then mean duration of cardiovascular hospitalizations on AAV1/SERCA2a is less than that on placebo (PϽ0.2).
The use of PϽ0.2 versus PϽ0.05 across multiple end points evaluated in this trial is justified because additional requirements were imposed on study outcomes to control for a probability of positive study results by chance alone. Success in any of the aforementioned 3 analyses had to be associated with the following: (1) at least a positive corresponding trend (numeric superiority) in all other analyses; (2) no clinically significant worsening of AAV1/ SERCA2a-treated patients in any of the end points; and (3) for group-level analysis, at least numeric superiority of AAV1/ SERCA2a-treated patients versus placebo in all corresponding domains. The combination of these requirements made it difficult to obtain positive study results randomly, as demonstrated by a permutation test. This permutation test was performed to estimate the uncertainty of obtaining the theoretical primary end point success criteria, as well as actual study results, by chance alone.
In addition to the analyses presented here, to account for timing of enrollment and different randomization ratios, the study's primary analyses were also stratified by randomization scheme and are presented in the online-only Data Supplement. 
Results
The 39 CUPID trial participants were randomized and received intracoronary infusion of AAV1/SERCA2a or placebo, allocated in numbers shown in Table 1 , along with demographics, baseline characteristics, and heart failure treatment regimen. This was a population with advanced heart failure, with an estimated 1-year mortality rate of Ϸ25%, according to risk profiles from other trials. 29, 30 All group-level analyses were adjusted for baseline values. Of note are some baseline differences for the placebo versus high-dose groups for important parameters such as V O 2 max and EF. The high-dose AAV1/SERCA2a group had a lower percentage of ␤-blocker usage (mainly because of comorbidities or intolerance).
A number of sensitivity analyses were conducted to test the potential impact of these imbalances on study results, and demonstrated that the baseline imbalances cannot explain any of the concordant positive outcomes in favor of the high-dose regimen, including the time to recurrent events analysis. These analyses, as well as descriptions of baseline imbalances, are discussed in detail in the online-only Data Supplement.
AAV1/SERCA2a Efficacy
The effects of AAV1/SERCA2a on the efficacy domains at 6, 9, and 12 months are depicted in Table 2 and Figure 2A through 2F; however, the end point success criterion for the primary analysis was prespecified at 6 months of follow-up. Although there was improvement (defined as at least numeric superiority) in some parameters in the low-and mid-dose groups, only the high-dose AAV1/SERCA2a group met all of the primary end point success criteria for the 6-month primary analysis. Patients on placebo consistently deteriorated over a 6-to 12-month period, whereas patients on the high-dose regimen either stabilized or improved. Deterioration in efficacy parameters on placebo over time was associated with a high rate of heart failure hospitalizations and increased risk of terminal events.
In the symptomatic efficacy domain, NYHA class was nearly unchanged, at Ϫ0.2Ϯ0.7, in the placebo group and improved in most treatment patients, with a mean decrease in the high-dose group of Ϫ0.6Ϯ0.7. Total scores for Minnesota Living With Heart Failure Questionnaire increased (worsened) in the placebo group by 3.4Ϯ36.0 points, whereas it decreased (improved) in the high-dose group by Ϫ10.3Ϯ12.2 points. In the functional domain, change from baseline to 6 months in the high-dose group was superior to that for placebo in the 6-minute walk test (Ϫ87Ϯ164 m for the placebo group versus 1Ϯ100 m for the high-dose group; Pϭ0.18), meeting the prospective criteria for success in this domain in the group-level analysis (PϽ0.2). At all 3 AAV1/ SERCA2a dose levels, there was a numeric superiority versus placebo in V O 2 max. In the biomarker domain, N-terminal prohormone brain natriuretic peptide increased in the placebo group by 5540Ϯ11 873 pg/mL and decreased in the highdose group by Ϫ14Ϯ928 pg/mL. In the LV function/remodeling domain, changes from baseline to 6 months in the high-dose group were superior to placebo in LV end-systolic volume, at 18Ϯ39 mL for the placebo group versus Ϫ10Ϯ28 mL for the high-dose group (Pϭ0.057). LVEF did not increase appreciably in any group but numerically was reduced to a greater extent in the placebo versus the high-dose group (Ϫ2.1Ϯ7% for the placebo group versus Ϫ0.7Ϯ4% for the high-dose group; Pϭ0.17). Both LV end-systolic volume and LVEF met the criteria for success in this domain in the group-level analysis. LV end-diastolic volume, a secondary prospectively defined end point, also improved significantly in high-dose versus placebo groups (16Ϯ29 mL for the placebo group versus Ϫ15Ϯ28 mL for the high-dose group; Pϭ0.011). The prespecified criterion for success was met in the individual-level analysis for the AAV1/SERCA2a high-dose group (but not the mid-and low-dose groups). In the placebo group, patients' mean individual efficacy score deteriorated by Ϫ1.2Ϯ3.0 points, whereas in high-dose patients, mean score improved by 1.1Ϯ2.0 points (Pϭ0.052, meeting the criteria for success in the individual-level analysis, PϽ0.2).
In the fifth efficacy domain, outcome end point, time to event (death, ventricular assist device placement, or heart transplantation) analysis was numerically in favor of AAV1/ SERCA2a. There were 2 events in the placebo group (ventricular assist device placement and death), 1 event in the mid-dose group (heart transplantation), and no events in 13 DNase-resistant particles AAV1/SERCA2a. *Domain Success Criteria Met: "Yes" identifies a domain for which success criteria are met (criteria: within a domain, active group compared with placebo shows improvement, PϽ0.2; another end point within this domain shows numerical superiority to placebo). Success in the group level analysis is achieved if there are at least 2 domains in which success criteria are met and there is no clinically significant worsening on AAV1/SERCA2a in any domain. P values are based on ANCOVA models with change from baseline as the dependent variables and baseline and treatment group as the independent variables. †⌬ϭPrespecified threshold for clinically significant difference. ‡Improvement of PϽ0.2. §Clinically significant worsening.
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the low-or high-dose groups. There was a reduction in the duration of cardiovascular hospitalizations in AAV1/ SERCA2a versus placebo (2.1Ϯ2.9 days in the placebo group versus 0.2Ϯ0.7 days in the high-dose group; Pϭ0.08, meeting the criteria for success for the Outcome End point, PϽ0.2). All beneficial effects of AAV1/SERCA2a versus placebo were further confirmed throughout 12 months of follow-up (Figure 2A through 2F ). An additional predefined analysis, time to multiple clinical events over time, is depicted in Figure 3 . Cardiovascular events in AAV1/SERCA2a-treated patients were either delayed or had a substantially reduced frequency or both. Of note, the 1 high-dose patient who received a transplantation had a low level of neutralizing antibody at baseline despite qualifying for the trial on this parameter during screening.
Recurrent clinical events in the low-and mid-dose groups were delayed versus placebo but have similar overall rates at 12 months. In contrast, the recurrent events in the high-dose group were both delayed and had a lower frequency than those in the placebo group at all time points. The hazard ratios and respective confidence intervals at 12 months versus placebo for recurrent clinical events adjusted for correlated terminal events (LV assist device, transplantation, death) are 0.40 (0.13 to 1.21) (Pϭ0.11), 0.44 (0.16 to 1.24) (Pϭ0.12), and 0.12 (0.03 to 0.49) (Pϭ0.003), representing risk reductions of 60%, 56%, and 88% for these important events with low-, mid-, and high-dose AAV1/SERCA2a, respectively.
Thus, the 6-month primary end point was achieved in all 3 of the prespecified analyses for the AAV1/SERCA2a highdose group, including the individual-level analysis, the group-level analysis (in functional and LV function/remodeling domains), and the outcome end point (duration of cardiovascular hospitalizations). On the basis of a permutation test, the probability of achieving success on the basis of the predefined requirements for all of the study primary end point success criteria by chance alone was 2.7%. However, the study results exceeded the predefined primary end point success criteria. On the basis of the actual study results, the probability of achieving the observed results for the high-dose group versus the placebo group by chance alone was Ͻ0.1%.
AAV1/SERCA2a Safety
AAV1/SERCA2a was well tolerated, and there were no untoward effects that could be attributed to AAV1/SERCA2a infusion. As of April 8, 2011, there were a total of 8 deaths in the trial, as detailed in the online-only Data Supplement; briefly, 4 occurred in the placebo group, 3 in the low-dose group, 1 in the mid-dose group, and 0 in the high-dose group.
The incidence of both serious adverse events and nonserious adverse events was inversely related to AAV1/SERCA2a dose, with the lowest incidence occurring in the high-dose patients and the highest incidence occurring in the placebo patients. Detailed patient safety data are presented in the online-only Data Supplement.
Discussion
In this small phase 2 study of 39 patients with advanced heart failure who were treated with a viral vector delivering the SERCA2a gene, we report a clinical signal of presumed enhanced biological activity of SERCA2a, as measured by several domains of efficacy, including a decrease in symptoms of heart failure, augmented functional status, a decrease in natriuretic peptide levels, and beneficial reverse remodeling of the LV. The high-dose group met the prospectively defined end points at the patient and group levels for improvement in abnormalities associated with advanced heart failure. There was no appreciable change in EF; however, both LV end-systolic volume and LV end-diastolic volume were substantially improved at 6 months after infusion in the high-dose group compared with placebo (LV end-systolic volume: ϩ18 versus Ϫ10 mL, Pϭ0.057; LV end-diastolic volume: ϩ16 versus Ϫ15 mL, Pϭ0.011, for placebo and high-dose groups, respectively). These improvements were concordant with delayed/reduced adjudicated clinical events in all 3 AAV1/SERCA2a groups. However, because EF is calculated on the basis of direct echocardiographically derived volume measurements, both limited sample size and compounded measurement errors for LV end-systolic volume and LV end-diastolic volume may have contributed to less accurate EF estimates. Improvement of EF estimates may be achieved in a larger clinical trial.
The impact of AAV1/SERCA2a on prevention of clinical outcomes is perhaps the most important finding from this study and will serve as the basis for the primary end point for confirmation of results of this small study in future trials. These prespecified clinical outcomes reached a statistically significant level in this group versus placebo at 12 months (Pϭ0.003). The decline in functional status in patients with cardiovascular clinical events (treatment failures) is amplified in the primary analysis because if follow-up data were missing after treatment failures, the values were imputed with the worst change observed in the study (detailed in the online-only Data Supplement). A blinded Morbidity and Mortality Committee reviewed and determined the causality of clinical outcomes including all-cause mortality, hospitalization for progression of heart failure, intravenous positive inotrope, vasodilator, diuretics, and/or peripheral ultrafiltration administered for symptoms of heart failure. Multiple cardiovascular events at 12 months. This figure represents the clinical course of a patient starting from the date of infusion of adeno-associated virus type 1(AAV1)/sarcoplasmic reticulum Ca 2ϩ -ATPase or placebo. Clinical events are depicted by symbols, and events occurring after 12 months are indicated by a hash sign (//). Each line represents a single patient whose cumulative follow-up of the active observation period plus long-term follow-up is depicted. An asterisk at the beginning of a line represents a patient with anti-AAV1 neutralizing antibody titer that was Ͻ1:2 during screening but Ն1:2 at baseline. WHF indicates worsening heart failure; MI, myocardial infarction; LVAD, left ventricular assist device; and NAb ϩ , positive for anti-AAV1 neutralizing antibody at baseline. The hazard ratios were calculated with a joint frailty model (see online-only Data Supplement for details). The hazard ratios and respective confidence intervals at 12 months versus placebo for recurrent clinical events adjusted for correlated terminal events (left ventricular assist device, transplantation, death) are 0.40 (0.13 to 1.21) (Pϭ0.11), 0.44 (0.16 to 1.24) (Pϭ0.12), and 0.12 (0.03 to 0.49) (Pϭ0.003) for low-dose (nϭ8), mid-dose (nϭ8), and high-dose (nϭ9) AAV1/sarcoplasmic reticulum Ca 2ϩ -ATPase, respectively (with nϭ14 in the placebo group).
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In this small study, the concordant positive signal across the 5 domains is supportive of the contention that administration of AAV1/SERCA2a induced meaningful biological activity. The results of the permutation analysis suggest that the multiple beneficial effects seen in the present study are unlikely to be the result of chance alone. We believe that these results form the basis for advancement of AAV1/ SERCA2a into larger pivotal trials.
In this trial, we examined the effects of correcting the enzymatic deficiency in myocardial SERCA2a levels in advanced heart failure patients via SERCA2a gene transfer using an AAV1 vector administered by a simple intracoronary infusion. Despite the fact that other AAV serotypes appear to be more cardiac specific 31, 32 in rodent studies, AAV1 is ideally suited for cardiac delivery. First, the cardiac tropism of serotypes such as AAV9 noted in rodents does not translate in large-animal studies (R.J. Hajjar, MD, written communication, 2009). Second, AAV1 does not bind heparin sulfate, 33 which has many relevant consequences, including the following: (1) Allowing passage of AAV1/SERCA2a freely through the interstitial space 34 is important for perfusion of the interior portions of the myocardium; (2) lacking the heparin sulfate binding domain avoids binding to dendritic cells and activation of capsid-specific T cells; 35 and (3) lack of heparin sulfate binding also avoids the liver tropism of AAV serotypes such as AAV6. 33 The administration method used here was found in the phase 1 trial to be safe and potentially effective. 20, 21 The safety data from this phase 2 trial support the earlier findings and demonstrate that previous concerns with gene therapy agents were not substantiated by the limited results from this study. It can be argued that we did not observe a clear dose response to the gene therapy. There are a number of potential reasons for this. Most importantly, AAV (like many macromolecules) exhibits cooperative binding (ie, affinity for its ligands changes with the amount of ligands already bound). This results in a steep dose-response curve and/or a threshold effect. In addition, the somewhat transient (6-month) benefit observed on clinical outcomes in the mid-and low-dose groups may be explained by transient effects of SERCA2a overexpression in coronary endothelial cells 18 at the blood interface, which may have a lower-dose threshold for transduction than deep myocardium. Improvement in coronary flow and vascular reactivity as a result of SERCA2a overexpression may have profound beneficial effects on a heart failure patient's cardiac and physical function. 18 This effect is expected to be transient because these vascular cells turn over, whereas cardiomyocytes do not. Most patients treated with AAV vectors develop a humoral immune response against the capsid proteins that has no apparent clinical sequelae other than as it relates to initial treatment and potential readministration. More importantly, we did not see evidence of a cellular immune response to the viral vector (by enzyme-linked ImmunoSPOT [ELISPOT] assay; see the online-only Data Supplement). On the basis of the prescreening of Ͼ500 patients, we would expect Ϸ50% of the systolic heart failure population to be ineligible for this potential therapy because of the presence of cross-reacting neutralizing antibodies to the viral vector capsid. We did not study viral shedding, but, on the basis of other AAV human trials, infectious viral particle shedding is expected to last Ϸ1 week. 36
Limitations
The CUPID trial consisted of only 39 patients and is limited with respect to our ability to conclusively prove that the delivered gene was responsible for the observed clinical effects. We were obligated to analyze the data of these 39 patients in an established but complex manner so that signals of biological activity could be detected. We sought to mitigate the small numbers of study patients by using core laboratories (see the online-only Data Supplement) and to use objective measures of efficacy including V O 2 max, biomarkers, and standardized quality-of-life questionnaires. Nevertheless, we recognize that the efficacy analysis used in this study is only recently becoming familiar to the heart failure community. Because this was a small study, larger confirmatory trials will need to be conducted to adequately assess the potential for this therapy in treating advanced heart failure.
Conclusions
In the CUPID trial, intracoronary administration of high-dose AAV1/SERCA2a to patients with advanced heart failure has shown concordant numeric trends toward clinically significant improvements in patients' symptoms and functional capacity, as well as a significant reduction of clinical events and hospitalization times. This was supported by reduction in N-terminal prohormone brain natriuretic peptide and improvement of cardiac structure. The study met its prespecified primary end point at both the group and patient levels, as well as in clinical outcomes.
Although there have been steady gains in the overall survival of patients with heart failure, few new approaches have reached the threshold of improving clinical outcomes in this population over the past decade, and there remains a need to explore novel therapeutic approaches. The results from the CUPID trial offer new hope for further advancing the treatment of chronic heart failure on the basis of a novel strategy of targeting SERCA2a. 
CLINICAL PERSPECTIVE
The Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) phase 2 randomized, double-blind trial evaluated adeno-associated virus type 1 (AAV1)/sarcoplasmic reticulum Ca 2ϩ -ATPase (SERCA2a) versus placebo in 39 patients. A deficiency in SERCA2a has been identified in cardiomyocytes from failing human hearts. AAV1/SERCA2a is a viral vector delivering the deficient SERCA2a gene by intracoronary infusion into patients with advanced heart failure. AAV1/SERCA2a in this study population demonstrated no untoward safety findings; there appeared to be fewer cardiovascular adverse events in the high-dose group compared with placebo. The study met the prospectively defined efficacy end points comprising 7 different parameters in 5 clinically relevant domains. All 3 predefined analyses were met at the individual-level, group-level (in functional and left ventricular function/remodeling domains), and clinical outcomes (duration of cardiovascular hospitalizations). High-dose AAV1/SERCA2a compared with placebo also demonstrated significantly delayed and reduced frequency of adverse cardiovascular events per patient, reaching statistical significance at 12 months (Pϭ0.003). The positive signals across 5 domains support the contention that high-dose AAV1/SERCA2a induced meaningful biological activity. Results from this small study indicate a decrease in symptoms of heart failure, augmented functional status, a decrease in natriuretic peptide levels, beneficial ventricular reverse remodeling, and a significant increase in time to and decreased frequency of adjudicated cardiovascular events in the high-dose group versus placebo. The totality of the data, limited by the small study size, strongly supports moving forward with confirmatory clinical studies of AAV1/SERCA2a for patients with severe heart failure. This CUPID trial represents a new approach to the treatment of heart failure with enzyme replacement via gene therapy. 
Additional Prospectively Defined Analyses
Time-to-multiple clinical events (worsening heart failure, myocardial infarction, heart failure hospitalization, cardiovascular death, LVAD and heart transplant) with overlapping events counted once, was compared between treatment groups at 12 months using the Joint Frailty
Model.
In clinical trials in general and the CUPID trial in particular, the unbiased assessment of a therapy impact on recurrent clinical events is confounded by the competing risk of terminal events such as death, LVAD, or heart transplantation and differential follow-up times between treatment groups. To overcome this challenge, a novel semi-parametric analysis that accounts for recurrent clinical events, unequal follow-up times between treatment groups, and terminal events (death, LVAD, heart transplant) as a competing risk has been applied to the CUPID trial data. A similar approach based on the Ghosh-Lin model 3 was used to analyze recurrent hospitalizations confounded by death in the COMPANION trial. 4 However, as stated in the COMPANION article, "The limitation of this methodology is that it does not provide a quantified measure of comparison between treatment groups (e.g., hazard ratio), yet it provides a log-rank P value comparing the hospitalization rates between groups." 4 The Joint Frailty Model utilized in the analysis of the CUPID data is free of this limitation. In computations of the hazard ratio, the respective confidence interval and p-value are unstable with a single event of worsening heart failure at day 0 in the high-dose group; therefore, day 1 was used instead of day 0 for timing of this event. This type of analysis has also been used in trials to account for multiple events such as tumor occurrence. 5 Days with/or a transplant, LVAD, hospitalization, or not alive was compared between treatment groups and placebo using analysis of variance model.
The Joint Frailty Model:
Primary End-point Analysis Method
The phase 2 primary endpoint success criteria is detailed below, and was prospectively defined as achieving efficacy in the intent to treat analysis in either the 1) Group Level Analysis, parameter within the domain, with no clinically significant worsening and numerical superiority versus placebo in all other endpoints.
Individual Level Analysis:
Clinically meaningful thresholds for each parameter are defined above. The numeric efficacy scores were calculated based on the number of parameters with clinically significant changes to 6 months; these scores were assigned to each parameter within the 4 efficacy domains for each patient:
 +1 -patient improved on a parameter from baseline to month 6 and the magnitude of improvement was greater or equal to the clinically meaningful threshold.
 -1 -patient worsened on a parameter from baseline to month 6 and the magnitude of worsening was greater or equal to the clinically meaningful threshold.
 0 -changes in a parameter were within the clinically meaningful threshold.
For each patient, the total numeric efficacy score was calculated as a sum of scores for all parameters within the four efficacy domains (NYHA class, MLWHFQ, 6-Minute-Walk test, VO 2 max, NT-proBNP, LVEF and LVESV). The range of possible scores for each patient was +7 to -7. The mean total efficacy score was calculated for each treatment group and placebo. The comparisons of mean total efficacy score at 6 months between each treatment group and placebo group was performed. The primary endpoint required superiority with statistical significance at the 0.2 level (2-sided).
Outcome Endpoint: Time-to-death (LVAD implantation or heart transplant) was
analyzed using the Kaplan-Meier approach. If the difference between a treatment group and placebo was not statistically significant at the 0.2 significance level, or the difference between respective median times to event was within 45 days, then the mean number of days of heart failure-related hospitalizations was compared between treatment groups and placebo. The primary endpoint required superiority at the 0.2 significance level.
If the endpoint of the study was achieved, a permutation test was to be performed in order to estimate the study false-positive rate. This was defined as the probability that differences between the successful dose(s) of AAV1/SERCA2a and placebo were observed by chance alone.
Permutation testing was performed under the hypothesis that no difference exists between AAV1/SERCA2a and placebo. Randomly simulated allocations of patients to AAV1/SERCA2a and placebo were repeated 1000 times and positive outcomes (pre-defined study successes) were counted.
ADDITIONAL STUDY INFORMATION: RANDOMIZATION AND TREATMENT ALLOCATION, CORE LABORATORIES AND STUDY INVESTIGATORS
Randomization and Treatment Allocation
Using a centralized unstratified randomization, patients were initially randomized in a double-blind, parallel fashion in a ratio of 8: additional patient was randomized to placebo and 1 additional patient was randomized to highdose AAV1/SERCA2a. These two randomizations created a final make-up of n=8 in low-dose AAV1/SERCA2a, n=8 in mid-dose AAV1/SERCA2a, n=9 in high-dose AAV1/SERCA2a and n=14 in placebo.
Core Laboratories
The following core laboratories were utilized in this study: hematology and serum Monitoring Committee was composed of two heart failure specialists, an interventionalist, an immunologist and a statistician.
SUPPLEMENTAL RESULTS:
Results Combining All Patients
The primary endpoint was achieved in all three of the pre-specified analyses for the high-dose group as follows: and left ventricular function domains (LVEF and LVESV). There were concordant trends in favor of high-dose versus placebo for all other parameters, and no clinically significant worsening on high-dose in any of the parameters.
Individual Level Analysis:
This pre-specified criterion for efficacy was met in the AAV1/SERCA2a high-dose group. In the placebo group, patients' mean Individual Efficacy Score deteriorated by -1.2 ± 3.0 points while in AAV1/SERCA2a high-dose patients, the mean score improved by +1.1 ± 2.0 (p=0.052). 
Outcome Endpoint:
Permutation Tests
Two permutation tests were performed: A permutation test to determine that the probability of achieving success based on the pre-defined requirements for all of the study primary endpoint success criteria by chance alone was 2.7%. However, the actual study results substantially exceeded the pre-defined primary endpoint success criteria, and based on the permutation test of the actual study results, the probability of achieving the observed study results for the high-dose group versus placebo by chance alone was <0.1% (assuming no difference between high-dose and placebo). 
Sensitivity Analyses
This was a randomized, double-blind study. Nevertheless, due to the relatively small sample size, some imbalances across treatment groups at baseline were noted in VO 2 max, NT-proBNP, end systolic volume and ejection fraction. However, as pre-specified in the statistical analysis plan, all Group-Level analyses were adjusted for baseline values. Additional sensitivity analyses were performed to evaluate the potential impact of these imbalances on study results and all the trends observed in the primary analyses were confirmed. All primary analyses were adjusted for baseline VO 2 max; time to recurrent events analyses were adjusted for baseline VO 2 max, 6 minute walk test, NT-proBNP, ejection fraction, and end systolic volume (one at a time due to small sample size). All trends were confirmed in these sensitivity analyses.
The high-dose AAV1/SERCA2a group had a lower percentage of beta-blocker usage; one patient had a co-morbidity preventing its use and two patients had a history of intolerance, one of which was later re-challenged at Week 5 on-study and able to tolerate the beta-blocker for the duration of the study. Of note, this patient had clinically significant improvement in NYHA Class, MLWHFQ, and NT-ProBNP from baseline by Week 4.
Several post-hoc sensitivity analyses were conducted in which the four "highest risk" placebo patients with the lowest VO 2 max, highest creatinine levels, and very high NT-proBNP were removed from the analysis. Baseline characteristics for these four patients are provided in Table 1 . Although this sensitivity analysis was severely biased in favor of placebo, all trends observed in favor of the high dose AAV1/SERCA2a group in the primary analysis were confirmed: in the Group Level (Table 3) , Individual-Level (Table 4 ) and outcome analyses the trends noted in the primary analyses were still all present. Some baseline imbalances in age (placebo patients were somewhat older) and cardiovascular history (higher proportion of patients with coronary artery disease, hypertension, myocardial infarction in the placebo group versus high-dose group) were not predictive of study results when analyses were stratified by these factors. Overall, both pre-specified adjustment for baseline values and additional sensitivity analyses have consistently shown that between-group differences in baseline values were not predictive of study outcomes.
A summary of the sensitivity analysis for the Group-Level Analysis is provided in Table 3 . There was still a trend in favor of the high-dose versus placebo groups for ALL seven efficacy parameters with the four highest risk placebo patients removed from the analyses. No clinically significant worsening (as pre-defined in the study Statistical Analysis Plan) was seen in the high-dose group for ANY of the seven efficacy parameters, and there was a trend toward improvement, while in the placebo group, substantial deterioration was observed. A sensitivity analysis was performed for the Individual Level analyses for the primary analysis at 6 months with the four highest risk placebo patients removed. A clinically-significant deterioration on placebo and clinically-significant improvement on high-dose AAV1/SERCA2a was still observed at both 6-month analyses, with a difference of about 2 points (based on the means). Results are provided in Table 4 .
The Time-to-Recurrent Events analysis was performed at the 6-, 9-and 12-month timepoints to compare the high-dose AAV1/SERCA2a to the placebo group, with and without the All trends were confirmed when 6-month primary analyses were adjusted for baseline imbalances in VO 2 max. Adjusted duration of cardiovascular hospitalizations of placebo versus high-dose was 1.9 days versus 0.5 days, p=0.199; Individual Level Analysis of placebo versus high-dose was -1.1 vs. +0.96, p=0.10; and, Time-to-Multiple Events of placebo versus high-dose has a hazard ratio of 0.21, p = 0.13.
Regarding age, trends in favor of high-dose versus placebo were stronger for patients greater than 60 years old for the Group-Level efficacy analysis. No trend differences were observed for patients with a cardiovascular history (CV history) of coronary artery disease, hypertension, and/or myocardial infarction compared to patients without history of these diseases/events.
To assess whether changes in the baseline LVESV or VO 2 max correlated with response in the high-dose patients, we compared each patients' 6-month Individual Efficacy Score with their baseline LVESV and VO 2 max (see Figures 1 and 2 ). There was no correlation between the Individual Efficacy Score and baseline LVESV or VO 2 max, and some of the best responders had high LVESV and low VO 2 max at baseline. Of note is the patient with positive AAV1 neutralizing antibody titer (NAb + ) who had the lowest Individual Efficacy Score at 6 months. 
Results: Stratification by Randomization Schemes
The AAV1/SERCA2a high-dose group was introduced after its safety was confirmed in the Phase 1 study. By that time 15 patients had been randomized into the study (Randomization 1) as follows: placebo (n=5), low-dose (n=4), and mid-dose (n=6). The remaining 24 patients were randomized (Randomization 2) as follows: placebo (n=9), low-dose (n=4), mid-dose (n=2) and high-dose (n=9). To account for timing of enrollment and different randomization ratios, the study primary analyses (Group Level, Individual Level, and duration of heart failure hospitalizations) were stratified by randomization scheme (Randomization 1 versus
Randomization 2). The respective outcomes for Randomization 2 were similar to (and actually exceeded) those observed in the analysis combining all patients regardless of their randomization scheme. Randomization 1 did not have high group patients. The results of Month 6 stratified primary efficacy analyses are presented in Table 5 , Table 6 and Table 7 for Group Level Analysis, Individual Level Analysis and Length of Cardiovascular-Related Hospitalizations, respectively, for all treatment groups.
Safety Results and Additional Patient Baseline Characteristics
Safety Results
Safety monitoring was performed weekly for the first month, and then at Week in mid-dose (1 in long-term follow-up). There were no deaths in the high-dose group.
The incidence of serious adverse events (SAEs) was 64% in placebo and 63%, 50% and 33% in AAV1/SERCA2a low-, mid-and, high-dose, respectively. The incidence of non-serious adverse events was 93% in placebo and 100%, 100% and 89% in AAV1/SERCA2a low-, mid-and, highdose, respectively (see Table 8 ).
A total of 10 patients (4 in placebo and 2 each in the AAV1/SERCA2a low-, mid-and high-dose groups) experienced at least one adverse event within 24 hours of the infusion as shown in Table 9 . The majority of the adverse events were mild in severity; 4 (anemia, cardiac failure, hypotension and rash macula-papular) were moderate. The one case of cardiac failure occurred in the AAV1/SERCA2A high dose group when increased right-sided intra-cardiac pressures were noted during the catheterization and angiography just prior to infusion; the patient was treated with IV diuretics and was discharged from the hospital the next day.
Additional baseline characteristics are shown in Table 10 . CUPID Investigators and Study
Coordinators are shown in Table 11 . Individual placebo patient values worse than both the mean study value and the mean placebo value are highlighted in bold font. 0.211 9 -3.6 (8.14) * Domain Success Criteria Met: "Yes" identifies a domain for which success criteria is met (criteria: within a domain active group compared to placebo shows improvement, p<0.2, another endpoint within this domain shows numerical superiority to placebo). Success in the group level analysis is achieved if there are at least two domains where success criteria are met and there is no clinically significant worsening on AAV1/SERCA2a in ANY domain. Note: P-values are based on ANCOVA models with change from baseline the dependent variables and baseline and treatment group as the independent variables. NOTE: Δ = Pre-specified threshold for clinically significant difference. Improvement of p<0.2 is underlined and in bold. Clinically significant worsening is in italic. NYHA, New York Heart Association; SD, standard deviation Note: L = Low = 6 x 10 11 Note: Percentages (%) are based on the number of patients in the treatment group. Note: A "treatment-emergent" AE began or worsened during or after administration of investigational product (IP). Note: An "IP-related" AE was possibly, probably, or definitely related to IP. Note: AAV1/SERCA2a Low=6 x 10 11 
